Long term data from four open label lacosamide extension trials reported at the 29th International Epilepsy Congress New non-interventional study (VITOBA TM) aims to investigate additive or ...

New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures ...

NEW ORLEANS – The anti-epileptic agent lacosamide (Vimpat) appears to give relief to patients with refractory trigeminal neuralgia, researchers reported here. Principal investigator Jeffrey Cohen, MD, ...

Motpoly XR is bioequivalent to Vimpat (lacosamide) film-coated tablets and provides a new once-daily option at equivalent doses. Motpoly XR™ (lacosamide) extended-release capsules are now available ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

Lacosamide 10mg/mL; strawberry-flavored; contains phenylalanine 0.32mg/20mL. The precise mechanism by which Vimpat exerts its antiepileptic effects in humans remains to be fully elucidated. In vitro ...

Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy - Vimpat(R) demonstrated greater seizure ...

Atlanta – March 11, 2010 – press release – UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in ...

ATLANTA, Nov. 30, 2010 /PRNewswire/ -- New data on UCB's anti-epileptic drug (AED) Vimpat® (lacosamide) C-V will be presented at the 64th annual meeting of the American Epilepsy Society (AES), taking ...

The US Food and Drug Administration (FDA) has approved a supplemental new drug application for the antiepileptic drug lacosamide (Vimpat, UCB) as monotherapy in treating partial-onset seizures in ...